3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
114
Carcinoma, Non-Small-Cell Lung
34
Neoplasms
26
Neoplasm Metastasis
19
Prostatic Neoplasms
18
Uveal Melanoma
16
Carcinoma, Renal Cell
16
Lung Neoplasms
14
Pancreatic Neoplasms
13
Diabetes Mellitus, Insulin-Dependent, 12
12
Small Cell Lung Carcinoma
11
Colorectal Neoplasms
10
Carcinoma, Hepatocellular
9
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Sarcoma
7
Carcinoma, Transitional Cell
7
Brain Neoplasms
7
Stomach Neoplasms
6
Mesothelioma
6
Kidney Neoplasms
6
Head and Neck Neoplasms
6
Advanced Cancer
6
Urinary Bladder Neoplasms
5
Recurrence
5
Ovarian Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Interventions
Cisplatin
33
Radiotherapy
23
Cetuximab
18
Paclitaxel
14
Docetaxel
14
pembrolizumab
13
Carboplatin
12
Fluorouracil
10
Radiotherapy, Intensity-Modulated
8
Nivolumab
8
Drug Therapy
7
Erlotinib Hydrochloride
6
Panitumumab
5
dacomitinib
4
Radiation
4
Methotrexate
4
Esophagectomy
4
130-nm albumin-bound paclitaxel
4
durvalumab
3
ON 01910
3
Leucovorin
3
Gemcitabine
3
Chemoradiotherapy
3
vandetanib
2
palbociclib
2
osimertinib
2
nedaplatin
2
fludarabine
2
cabazitaxel
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Squamous Cell
×
Ipilimumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts